CY1110418T1 - Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους - Google Patents

Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους

Info

Publication number
CY1110418T1
CY1110418T1 CY20081101332T CY081101332T CY1110418T1 CY 1110418 T1 CY1110418 T1 CY 1110418T1 CY 20081101332 T CY20081101332 T CY 20081101332T CY 081101332 T CY081101332 T CY 081101332T CY 1110418 T1 CY1110418 T1 CY 1110418T1
Authority
CY
Cyprus
Prior art keywords
interaction
proteins
oxidated
suspension
action
Prior art date
Application number
CY20081101332T
Other languages
English (en)
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur filed Critical Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur
Publication of CY1110418T1 publication Critical patent/CY1110418T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ουσίες, οι οποίες αναστέλλουν την σύνδεση οξειδωμένων πρωτεϊνών σε CD36 ή τις λειτουργίες από CD36 που διεγείρονται με την αλληλεπίδραση CD36 με οξειδωμένες πρωτεΐνες και τη χρησιμοποίηση τους σαν φάρμακα για ανθρώπους και ζώα.
CY20081101332T 2000-10-20 2008-11-19 Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους CY1110418T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
EP01983562A EP1328289B1 (de) 2000-10-20 2001-10-19 Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36

Publications (1)

Publication Number Publication Date
CY1110418T1 true CY1110418T1 (el) 2015-04-29

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101332T CY1110418T1 (el) 2000-10-20 2008-11-19 Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους

Country Status (14)

Country Link
EP (2) EP1328289B1 (el)
JP (1) JP4881535B2 (el)
AP (2) AP2034A (el)
AT (1) ATE406908T1 (el)
AU (1) AU2002215032A1 (el)
CA (1) CA2453140C (el)
CY (1) CY1110418T1 (el)
DE (1) DE50114289D1 (el)
DK (1) DK1328289T3 (el)
ES (1) ES2307662T3 (el)
HK (1) HK1057857A1 (el)
OA (1) OA12431A (el)
PT (1) PT1328289E (el)
WO (1) WO2002032445A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375601T3 (es) * 2003-04-25 2012-03-02 Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur Lucha contra infecciones por virus de ih con plasma sangu�?neo humano oxidado con �?cido hipocloroso.
CN102552874B (zh) * 2005-09-16 2015-04-22 科内尔研究基金会 用于减少cd36表达的方法
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
WO1991005536A2 (en) * 1989-10-06 1991-05-02 The Beth Israel Hospital Association Novel oxidized lipoproteins and methods for their preparation
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
AU7185191A (en) * 1990-01-08 1991-08-05 Schering Corporation Oxidized variants of gm-csf
EP0539506A4 (en) * 1990-07-18 1993-11-24 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
CA2176005A1 (en) 1993-11-08 1995-05-18 Trevor G. Redgrave Labelled diagnostic compositions and methods of their use
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
AU3442397A (en) 1997-06-20 1999-01-04 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU1243500A (en) * 1998-11-06 2000-05-29 Emory University Biomarkers for oxidative stress
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Also Published As

Publication number Publication date
JP2004511526A (ja) 2004-04-15
AP2009004857A0 (en) 2009-06-30
AP2781A (en) 2013-10-31
CA2453140A1 (en) 2002-04-25
HK1057857A1 (en) 2004-04-23
AU2002215032A1 (en) 2002-04-29
AP2003002795A0 (en) 2003-06-30
PT1328289E (pt) 2008-12-10
EP1994941A3 (de) 2012-07-25
DE50114289D1 (de) 2008-10-16
AP2034A (en) 2009-08-28
JP4881535B2 (ja) 2012-02-22
ATE406908T1 (de) 2008-09-15
DK1328289T3 (da) 2008-12-15
EP1328289B1 (de) 2008-09-03
OA12431A (en) 2006-04-19
EP1328289A2 (de) 2003-07-23
EP1994941A2 (de) 2008-11-26
CA2453140C (en) 2016-01-05
WO2002032445A3 (de) 2003-04-17
ES2307662T3 (es) 2008-12-01
WO2002032445A2 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1115731T1 (el) Παραγοντας αναστολης toy mic-1
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1107505T1 (el) Πουρινικες ενωσεις και χρησεις τους ως προσδεματα υποδοχεων κανναβιδοειδων
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
DK1487856T3 (da) KDR-specifikke humane antistoffer og deres anvendelse
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
CY1110609T1 (el) Μεθοδος για την παρασκευη μιας διασφαλισμενης εναντια σε καταχρηση μορφης χορηγησης
CY1107717T1 (el) Συνδυασμοι και συνθεσεις που παρεμποδιζουν τη λειτουργια υποδοχεα vegf/vegf και αγγειοποιητινης/tie και η χρηση τους (ιι)
CY1120424T1 (el) Πεπτιδια λαμβανομενα απο ανθρωπινη bplp πρωτεϊνη, πολυνουκλεοτιδια που κωδικοποιουν τα εν λογω πεπτιδια και αντισωματα κατευθυνομενα εναντι των εν λογω πεπτιδιων
ES2333598T5 (es) Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
CY1106070T1 (el) Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon